LTR Pharma Limited (LTP)
Market Closed
ASX ASX Primary CXA 72.71M Market Cap
- P/E Ratio
- Div Yield
108,468 Volume
- Eps
Want to track LTP and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
LTP is not paying dividends to its shareholders.
The last earnings report, released on Aug 28, 2025, missed the consensus estimates by -0.02%. On average, the company has fell short of earnings expectations by -0.02%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 2 different exchanges and in various currencies, with the primary listing on ASX (AUD).
LTR Pharma Limited (LTP) FAQ
On which exchange is it traded?
LTR Pharma Limited is listed on ASX.
What is its stock symbol?
The ticker symbol is LTP.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 72.71M.
Has LTR Pharma Limited ever had a stock split?
No, there has never been a stock split.
LTR Pharma Limited Profile
| Health Care Equipment & Supplies Industry | Healthcare Sector | Mr. Lee Rodne CEO | ASX Exchange | AU0000305294 ISIN |
| AU Country | - Employees | - Last Dividend | - Last Split | - IPO Date |
LTR Pharma Limited, a clinical-stage pharmaceutical company, engages in the research and development of intranasal spray for the treatment erectile dysfunction (ED) in Australia. Its lead product candidate is SPONTAN, an intranasal delivery technology, an oral PDE5 inhibitor and vardenafil HCL for the treatment of ED. The company was incorporated in 2020 and is headquartered in Brisbane, Australia.
Contact Information
Address: 29/97 Creek Street, Brisbane, QLD, Australia, 4000
Phone: 61 18 0051 9711
Website: https://www.ltrpharma.com
